Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AgfiledCriticalSchering Ag
Priority to UY26539ApriorityCriticalpatent/UY26539A1/en
Publication of UY26539A1publicationCriticalpatent/UY26539A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Una composición farmacéutica que comprende como un primer ingrediente activo un estrógeno, tal como estradiol o valerato de estradiol, en cantidades suficientes para tratar desórdenes y síntomas asociados con niveles endógenos deficientes de estrógeno en mujeres, y como un segundo ingrediente activo 6b, 7b; 15b; 16b-dimentil-3-oxo-17a-preg-4-eno-21, 17-carbolactona (drospirenona, DRSP) en cantidades suficientes para proteger el endometrio de los efectos adversos del estrógeno.A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in amounts sufficient to treat disorders and symptoms associated with endogenous estrogen deficient levels in women, and as a second active ingredient 6b, 7b; 15b; 16b-dimethyl-3-oxo-17a-preg-4-ene-21, 17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen.
UY26539A2001-01-152001-01-15
DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY.
UY26539A1
(en)
USE OF GESTAGENS IN COMBINATION WITH (6S) -5-METHYL-TETRAHYDROPHOLATE FOR THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPEUTIC COLLATERAL EFFECTS AND REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS AT THE BEGINNING OF BEGIN
17ALFA - FLUOROSTEROIDS WITH INHIBITING ACTIVITY OF 5 ALFA-REDUCTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF CANCER DISEASES INFLUENCED BY ANDROGENS.